Literature DB >> 11229455

Involvement of ErbB-2 in rheumatoid synovial cell growth.

K Satoh1, S Kikuchi, M Sekimata, Y Kabuyama, M K Homma, Y Homma.   

Abstract

OBJECTIVE: The synovial tissue affected by rheumatoid arthritis (RA) is characterized by hyperproliferation of synovial cells. High amounts of epidermal growth factor (EGF) in the synovial fluid of RA patients contribute to the growth of rheumatoid synovial cells. To characterize the receptor for EGF in rheumatoid synovial cells, the expression and function of ErbB family members were examined.
METHODS: Synovial tissues were obtained from surgical excisions. The expression of ErbB products was examined by immunohistochemistry and immunoblotting by using specific antibodies. Primary cultures were established from the surgical materials. Cell growth was measured using MTT. The levels and phosphorylation state of the ErbB-2 protein were analyzed by immunoprecipitation and immunoblotting.
RESULTS: The expression of ErbB-2, but not other ErbB-related products, was detected in synovium with RA as compared with that with osteoarthritis (OA) and ligament injury. Growth of primary synovial cells with RA was inhibited by genistein, a tyrosine kinase inhibitor, and herceptin, a specific monoclonal antibody against ErbB-2. Herceptin showed a small effect on growth of primary synovial cells with OA. EGF stimulated the phosphorylation of ErbB-2 in primary synovial cells with RA. This EGF-stimulated phosphorylation was completely abrogated by genistein and herceptin.
CONCLUSION: ErbB-2 is expressed in rheumatoid synovial cells and may function as the receptor for EGF. Our data suggest that mitotic signals from EGF family members are transduced by ErbB-2 in these cells. Inhibition of ErbB-2 may provide a new approach to the effective treatment for RA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11229455     DOI: 10.1002/1529-0131(200102)44:2<260::AID-ANR42>3.0.CO;2-P

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  13 in total

1.  Identification of potential peripheral blood diagnostic biomarkers for patients with juvenile idiopathic arthritis by bioinformatics analysis.

Authors:  Zhi-Qiang Tu; Hai-Yan Xue; Wei Chen; Lan-Fang Cao; Wei-Qi Zhang
Journal:  Rheumatol Int       Date:  2016-11-19       Impact factor: 2.631

2.  Trisomy 7 in synovial fluid cells of patients with rheumatoid arthritis.

Authors:  Funda Tascioglu; Beyhan Durak; Cengiz Oner; Sevilhan Artan
Journal:  Rheumatol Int       Date:  2004-06-25       Impact factor: 2.631

3.  Protein biochip array technology to monitor rituximab in rheumatoid arthritis.

Authors:  S Fabre; C Guisset; L Tatem; N Dossat; A M Dupuy; J D Cohen; J P Cristol; J P Daures; C Jorgensen
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

4.  Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.

Authors:  S Fabre; A M Dupuy; N Dossat; C Guisset; J D Cohen; J P Cristol; J P Daures; C Jorgensen
Journal:  Clin Exp Immunol       Date:  2008-06-18       Impact factor: 4.330

5.  Epidermal growth factor increases prostaglandin E2 production via ERK1/2 MAPK and NF-kappaB pathway in fibroblast like synoviocytes from patients with rheumatoid arthritis.

Authors:  Seong-Su Nah; Hye-Jin Won; Eunyoung Ha; Insug Kang; Hong Yon Cho; Sook-Jin Hur; Sang-Hoon Lee; Hyung Hwan Baik
Journal:  Rheumatol Int       Date:  2009-08-13       Impact factor: 2.631

6.  Lapatinib ameliorates experimental arthritis in rats.

Authors:  Metin Ozgen; Suleyman Serdar Koca; Ahmet Karatas; Adile Ferda Dagli; Fazilet Erman; Baris Gundogdu; Kazim Sahin; Ahmet Isik
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

7.  Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.

Authors:  Ricardo T Paniagua; Orr Sharpe; Peggy P Ho; Steven M Chan; Anna Chang; John P Higgins; Beren H Tomooka; Fiona M Thomas; Jason J Song; Stuart B Goodman; David M Lee; Mark C Genovese; Paul J Utz; Lawrence Steinman; William H Robinson
Journal:  J Clin Invest       Date:  2006-09-14       Impact factor: 14.808

8.  Microsomal prostaglandin e synthase-1 in rheumatic diseases.

Authors:  Marina Korotkova; Per-Johan Jakobsson
Journal:  Front Pharmacol       Date:  2011-01-20       Impact factor: 5.810

9.  Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade.

Authors:  Luke L Gompels; Nasser M Malik; Leigh Madden; Pei Jin; Marc Feldmann; H Michael Shepard; Ewa M Paleolog
Journal:  Arthritis Res Ther       Date:  2011-10-07       Impact factor: 5.156

10.  ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease.

Authors:  Yuriko Iwakura; Hiroyuki Nawa
Journal:  Front Cell Neurosci       Date:  2013-02-13       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.